Human Health Therapeutics Research Centre, National Research Council of Canada, Montreal, Canada.
Bioprocess Biosyst Eng. 2022 Aug;45(8):1267-1280. doi: 10.1007/s00449-022-02737-5. Epub 2022 Jun 27.
The growing interest in the use of lentiviral vectors (LVs) for various applications has created a strong demand for large quantities of vectors. To meet the increased demand, we developed a high cell density culture process for production of LV using stable producer clones generated from HEK293 cells, and improved volumetric LV productivity by up to fivefold, reaching a high titer of 8.2 × 10 TU/mL. However, culture media selection and feeding strategy development were not straightforward. The stable producer clone either did not grow or grow to lower cell density in majority of six commercial HEK293 media selected from four manufacturers, although its parental cell line, HEK293 cell, grows robustly in these media. In addition, the LV productivity was only improved up to 53% by increasing cell density from 1 × 10 and 3.8 × 10 cells/mL at induction in batch cultures using two identified top performance media, even these two media supported the clone growth to 5.7 × 10 and 8.1 × 10 cells/mL, respectively. A combination of media and feed from different companies was required to provide diverse nutrients and generate synergetic effect, which supported the clone growing to a higher cell density of 11 × 10 cells/mL and also increasing LV productivity by up to fivefold. This study illustrates that culture media selection and feeding strategy development for a new clone or cell line can be a complex process, due to variable nutritional requirements of a new clone. A combination of diversified culture media and feed provides a broader nutrients and could be used as one fast approach to dramatically improve process performance.
慢病毒载体 (LV) 在各种应用中的应用日益受到关注,这对大量载体产生了强烈的需求。为了满足这一需求,我们开发了一种从 HEK293 细胞生成的稳定生产细胞克隆的高密度细胞培养工艺,用于生产 LV,并将 LV 的体积生产率提高了五倍,达到 8.2×10 TU/mL 的高滴度。然而,培养基选择和补料策略的开发并不简单。在从四家制造商中选择的六种商业 HEK293 培养基中,稳定生产细胞克隆要么无法生长,要么生长到较低的细胞密度,尽管其亲本细胞系 HEK293 细胞在这些培养基中生长良好。此外,通过在批式培养中从 1×10 和 3.8×10 个细胞/mL 开始诱导时,将细胞密度增加到 5.7×10 和 8.1×10 个细胞/mL,仅使用两种鉴定的最佳性能培养基,LV 的生产率仅提高了 53%,即使这两种培养基分别支持克隆生长到 5.7×10 和 8.1×10 个细胞/mL。需要来自不同公司的培养基和补料的组合,以提供不同的营养物质并产生协同作用,从而支持克隆生长到更高的细胞密度 11×10 个细胞/mL,并将 LV 生产率提高五倍。本研究表明,由于新克隆的营养需求不同,新克隆或细胞系的培养基选择和补料策略的开发可能是一个复杂的过程。多样化的培养基和补料的组合提供了更广泛的营养物质,可以作为一种快速提高工艺性能的方法。